Show
Sort by
-
Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases
-
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
-
- Conference Paper
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft model analysed by SPECT imaging
-
- Conference Paper
- C3
- open access
PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?
-
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)
-
Diffusion magnetic resonance imaging as surrogate marker to anti-VEGF treatment response in MCTC
-
PET evaluation of anti-VEGF treatment in combination with chemotherapy in MCRC
-
Comparison of two contrast agents for DCE-MRI evaluation of anti-VEGF treatment in combination with chemotherapy in MCRC